Recent Updates
Recently added Catalysts
AMGN

Amgen to Present at the Citi 2011 Global Healthcare Conference Amgen (Nasdaq: AMGN) will participate in the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011, at the Hilton Club New York in New...

Key Takeaway: THOUSAND OAKS, Calif. , Feb. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) will participate in the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011 , at the Hilton Club New York in New York City , beginning at 11:30 a.m. Eastern Time . Rolf Hoffmann , senior vice

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+30%
120-day peak, hindsight
Typical move
1.4%
average across 15 past catalysts
Lead asset
Maridebart cafraglutide
Phase 3 · Heart Failure With Preserved Ejection Fraction

Full Press Release Details

THOUSAND OAKS, Calif. , Feb. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN ) will participate in the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011 , at the Hilton Club New York in New York City , beginning at 11:30 a.m. Eastern Time . Rolf Hoffmann , senior vice president, International Commercial Operations and Arvind Sood , vice president, Investor Relations will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com , under Investors.
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com .
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
John Shutter, 805-447-1060 (investors)
Last updated: Feb 24, 2011